Multicentre, Open Label, Prospective, Randomised Clinical Trial of an Antiretroviral Simplification Treatment With Efavirenz + Abacavir + 3TC [lamivudine] Once Daily

Trial Profile

Multicentre, Open Label, Prospective, Randomised Clinical Trial of an Antiretroviral Simplification Treatment With Efavirenz + Abacavir + 3TC [lamivudine] Once Daily

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2010

At a glance

  • Drugs Efavirenz (Primary) ; Lamivudine/abacavir (Primary) ; Nucleoside reverse transcriptase inhibitors
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jan 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 09 Nov 2008 48-week results were presented at the 9th International Congress on Drug Therapy in HIV Infection.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top